|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_ocn930023638 |
| 003 |
OCoLC |
| 005 |
20231120112035.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
151120t20162016maua ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d YDXCP
|d IDEBK
|d OPELS
|d N$T
|d OCLCF
|d EBLCP
|d CDX
|d CDN
|d OCLCO
|d OCLCO
|d OCLCQ
|d OCLCA
|d U3W
|d AU@
|d OCLCO
|d MERER
|d OCLCO
|d WYU
|d OCLCO
|d OCLCA
|d OCLCQ
|d OCLCA
|d OCLCQ
|d LQU
|d OCLCQ
|d OCLCO
|d COM
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 932332323
|a 936958966
|a 1066573451
|a 1105189425
|a 1105571508
|
| 020 |
|
|
|a 9780128017579
|q (electronic bk.)
|
| 020 |
|
|
|a 0128017570
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128015773
|
| 020 |
|
|
|z 0128015772
|
| 035 |
|
|
|a (OCoLC)930023638
|z (OCoLC)932332323
|z (OCoLC)936958966
|z (OCoLC)1066573451
|z (OCoLC)1105189425
|z (OCoLC)1105571508
|
| 050 |
|
4 |
|a QR181
|b .T74 2016eb
|
| 060 |
|
4 |
|a QW 540
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.07/9
|2 23
|
| 245 |
0 |
0 |
|a Translational immunology :
|b mechanisms and pharmacologic approaches /
|c edited by Seng-Lai Tan.
|
| 264 |
|
1 |
|a Waltham, MA :
|b Academic Press is an imprint of Elsevier,
|c [2016]
|
| 264 |
|
4 |
|c �2016
|
| 300 |
|
|
|a 1 online resource (xiv, 370 pages) :
|b color illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (ScienceDirect, viewed December 15, 2015).
|
| 505 |
0 |
|
|a Front Cover; Translational Immunology: Mechanisms and Pharmacologic Approaches; Copyright; Contents; Contributors; Preface; Section A: Human Immunology; Chapter 1: Systems Immunology; 1. Introduction; 2. Immune System is a Distributed and Decentralized Network that Protects Against Disease and Provides a Readout on Health; 2.1. Immune cells are distributed and specialized; 2.2. Immune system connects to all aspects of health and disease; 2.3. Commensal organisms; 2.4. Infectious diseases; 2.5. Allergic diseases; 2.6. Autoimmune diseases; 2.7. Inflammatory diseases; 2.8. Cancer
|
| 505 |
8 |
|
|a 2.9. Metabolic diseases2.10. Neurological diseases; 2.11. Connections between the immune system and other organ systems; 3. High-Throughput Technologies and Techniques for Systems Immunology; 3.1. Genomic profiling of immune system genes; 3.2. Transcriptional profiling of immune cells; 3.3. High-throughput technologies to profile immune cells; 4. Controlling the Immune System to treat Disease; 4.1. Vaccination to control infectious disease; 4.2. Immunotherapy to manipulate surveillance and control cancer; 4.3. Biologics to control autoimmune disease
|
| 505 |
8 |
|
|a 4.4. Drugs or other therapeutics to control asthma and allergy4.5. Drugs or other therapeutics to aid transplantation and resist rejection; 4.6. Drug repurposing; 4.7. Cellular therapies; 5. Immune monitoring; 5.1. Understanding global health challenges; 5.2. Predicting, tracking, and preventing emerging epidemics; 5.3. Identifying baseline states; 5.4. Monitoring for healthy aging and longevity; 5.5. Monitoring for critical care situations; 6. Conclusion; References; Chapter 2: Congenital Immunodeficiency Diseases: Crossroad of Infection, Autoimmunity, and Hyperinflammation; 1. Introduction
|
| 505 |
8 |
|
|a 2. Clinical Features of Autoimmune and Inflammatory Manifestations in PID3. Mechanisms Leading to Autoimmunity and Hyperinflammation in PID; 3.1. Increased apoptosis and decreased clearance; 3.1.1. Complement defects; 3.1.2. Chronic granulomatous disease (CGD); 3.2. Tendency for hyperinflammation; 3.2.1. Chronic granulomatous disease (CGD); 3.2.2. Omenn syndrome; 3.3. Impaired B or T cell tolerance checkpoints; 3.3.1. Defects in B cell tolerance that induce autoimmunity in PID; 3.3.2. Defects in T cell tolerance that induce autoimmunity in PID
|
| 505 |
8 |
|
|a 3.3.3. Defects in multiple tolerance checkpoints that induce autoimmunity in PID4. Current treatment strategies for autoimmunity in PID; 5. Investigational treatment strategies for autoimmunity in PID; 5.1. Small molecule inhibitors; 5.2. Gene therapy; 5.3. Cell-based therapy; 5.3.1. T regulatory Type 1 (Tr1) cells; 5.3.2. Virus-specific T cells; 6. Summary Statement; References; Chapter 3: Phenome-Wide Association Study; 1. Introduction; 2. Phenotyping from the Medical Record; 2.1. History of the classification of the human phenome; 2.2. Phenotyping from ICD data
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
|
0 |
|a Immunopharmacology.
|
| 650 |
|
2 |
|a Immunity
|x drug effects
|0 (DNLM)D007109Q000187
|
| 650 |
|
2 |
|a Immunotherapy
|x methods
|0 (DNLM)D007167Q000379
|
| 650 |
|
2 |
|a Translational Research, Biomedical
|0 (DNLM)D057170
|
| 650 |
|
2 |
|a Allergy and Immunology
|0 (DNLM)D000486
|
| 650 |
|
6 |
|a Immunologie.
|0 (CaQQLa)201-0066630
|
| 650 |
|
6 |
|a Immunopharmacologie.
|0 (CaQQLa)201-0072475
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Immunology
|2 fast
|0 (OCoLC)fst00968006
|
| 650 |
|
7 |
|a Immunopharmacology
|2 fast
|0 (OCoLC)fst00968030
|
| 700 |
1 |
|
|a Tan, Seng-Lai,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|a Tan, Seng-Lai.
|t Translational Immunology : Mechanisms and Pharmacologic Approaches.
|d : Elsevier Science, �2015
|z 9780128015773
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128015773
|z Texto completo
|
